granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

the administrative expenses category. Selling Expenses, especially the advertising and promotion costs will depend on the period of campaigns, new product launch, etc. Due to a great impact from the

decreased from Q2–2019. This is because several projects in Q2–2020 were affected by the ongoing outbreak of COVID–19, forcing many customers to adjust their working method which have an effect on the

sector remained challenged by new modes of competition in a broader marketplace amid the advancing digital age and its rapid pace of technological advancement. Businesses have also had to cope with Thai

100.0% 12,622 100.0% 1,921 18.0% Total Cost of Sales and Services 8,729 81.6% 10,030 79.5% 1,301 14.9% Gross Profit 1,972 18.4% 2,593 20.5% 621 31.5% Sale Promotion Income 438 4.1% 511 4.0% 73 16.6% Other

. For the business trend would gradually improve due to the Company had launched the 30th-anniversary promotion of Jaymart and expanded the distribution channels with lower costs such as direct sales to

. For the business trend would gradually improve due to the Company had launched the 30th-anniversary promotion of Jaymart and expanded the distribution channels with lower costs such as direct sales to

partner to operate SIM business. For Q3 and Q4 of this year, there will be still the high season of sales. Besides, the Company has launched the 30th-anniversary promotion of Jaymart in order to stimulate

% Sale Promotion Income 134.5 4.6% 90.0 2.9% -44.5 -33.1% Other Incomes 31.3 1.1% 30.1 1.0% -1.2 -3.8% Profit before Expenses 747.1 25.3% 779.3 25.0% 32.2 4.3% Selling Expenses 218.9 7.4% 237.5 7.6% 18.6